AN2 Therapeutics Inc

10-Year Study

ANTX.US · Healthcare · US · Common Stock

Executive Summary: AN2 Therapeutics Inc has compounded at -31.9% annually over the last 10 years, with a maximum drawdown of 94.8% and an annualized volatility of 384.9%.

1Y CAGR
+226.7%
3Y CAGR
-18.0%
5Y CAGR
-31.9%
10Y CAGR
-31.9%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
94.8%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.40
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.88
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
147.5%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +175.4%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2024 · -93.3%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
50%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-0.9-2.7210.9-8.2————————175.4%
2025-17.40.019.3-8.8-14.50.00.03.815.5-3.1-11.44.6-17.4%
2024-5.8-84.69.1-26.2-17.18.018.6-55.7-5.30.954.6-17.4-93.3%
202327.6-7.2-12.5-20.5-28.551.5-4.585.26.9-10.321.816.6115.0%
2022———3.7-4.0-48.310.5100.21.4-17.0-30.9-4.4-36.8%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 384.9%. The dominant macroeconomic risk driver is SHV.US, accounting for 75.2% of variance. Idiosyncratic stock-specific factors contribute 6.1%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2022-03-0110000
2022-04-0110371.599489686141
2022-05-019953.550301100364
2022-06-015142.667655568522
2022-07-015680.159650273003
2022-08-0111373.58973904635
2022-09-0111532.846391984833
2022-10-019568.679740084192
2022-11-016615.793277323687
2022-12-016323.822114106786
2023-01-018069.011342839279
2023-02-017485.069649235162
2023-03-016549.436022184477
2023-04-015209.02459429289
2023-05-013722.6279012076925
2023-06-015640.34517062354
2023-07-015388.188487056102
2023-08-019980.09307659011
2023-09-0110670.205872153216
2023-10-019568.679740084192
2023-11-0111658.925050183392
2023-12-0113596.549559423975
2024-01-0112806.900881152054
2024-02-011977.4386724751994
2024-03-012156.6025652384124
2024-04-011592.5681114590268
2024-05-011320.5043462742785
2024-06-011426.6756064406875
2024-07-011692.1035195455777
2024-08-01749.8341195187456
2024-09-01710.0199562841253
2024-10-01716.6556501565622
2024-11-011108.1619050451714
2024-12-01915.7266245370852
2025-01-01756.4698133911824
2025-02-01756.4698133911824
2025-03-01902.4552367922116
2025-04-01822.8268312192604
2025-05-01703.3841833079779
2025-06-01703.3841833079779
2025-07-01703.3841833079779
2025-08-01729.9270379014355
2025-09-01842.7339128365704
2025-10-01816.1911373468237
2025-11-01723.2913440289989
2025-12-01756.4698133911824
2026-01-01749.8341195187456
2026-02-01729.9270220806934
2026-03-012269.409468650883
2026-04-012083.6098630303427
Annual Return Matrix
YearAnnual Return
20231.150052502124252
2024-0.9326500726868324
2025-0.1739130509898733
20261.7543859994752702
Total Factor Risk
3.848611471171041
VTI.US Exposure
0.003548466454707031
VEA.US Exposure
-0.007110894220577417
VWO.US Exposure
0.027354098488565518
QQQ.US Exposure
0.005536611669120368
VTV.US Exposure
-0.0012012886973483642
IJR.US Exposure
0.002697684730409111
QUAL.US Exposure
0.05789241968877002
SHV.US Exposure
0.7515889495759807
TLT.US Exposure
0.013689047245504385
LQD.US Exposure
0.05185945448431668
HYG.US Exposure
0.01438999361532256
GLD.US Exposure
0.0025098269993363486
USO.US Exposure
0.010151958136832557
VNQ.US Exposure
-0.0002388225024072096
BTC-USD.CC Exposure
0.0002645670522469146
CPER.US Exposure
-0.0014070335124021598
VIX.INDX Exposure
0.0010591295983144009
UUP.US Exposure
0.006106867654945005
TIP.US Exposure
0.00004091201734611581
Idiosyncratic Exposure
0.06126805152101752
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
384.9%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$117.5M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+16.2%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+103.3%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
42.5% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
-1.32
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is AN2 Therapeutics Inc a high-risk investment?

AN2 Therapeutics Inc (ANTX.US) has an annualized volatility of 384.9% and experienced a maximum drawdown of 94.8% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of ANTX.US?

Over the past 10 years, ANTX.US has generated a Compound Annual Growth Rate (CAGR) of -31.9%. It has had a positive return in 50% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on AN2 Therapeutics Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest